April 21, 2026

@michaelokun

Semaglutide and Alzheimer’s: are we seeing signals in the brain biology? Semaglutide is a GLP-1 analog, which means it mimics a hormone involved in metabolism and may also influence inflammation and brain cell health. Dylan Belmont-Rausch and colleagues describe new data presented at the AAN Annual Meeting in Chicago this week exploring how semaglutide may impact Alzheimer’s disease biology using biofluid biomarkers and multiomics immune profiling over a 12 week period. Key points: - Semaglutide reduced key CSF biomarkers linked to Alzheimer’s pathology including p-tau181, t-tau and neurogranin after 12 weeks. - There were no significant differences in overall gene expression changes between treatment and placebo groups in blood and CSF. - Immune profiling suggested a shift toward less inflammatory states, including reduced NK cell signaling and altered CD8+ T cell activity. My take: This is an intriguing early signal study. There are possible biological effects in fluid markers and immune pathways over a short time window. The lack of broad gene expression changes should remind us that mechanisms may be subtle and targeted. The real question will be whether these biomarker shifts translate into clinical benefit over longer periods. Here are 5 points that resonated w/ me: 1- Early Alzheimer’s may be influenced by metabolic and immune pathways, not just amyloid and tau. 2- Biomarker changes in CSF may offer a readout of whether a therapy is hitting its biological target. 3- Immune system shifts toward less inflammation may be an important pathway for slowing disease progression. 4- Small sample sizes and short duration mean we should be cautious in interpreting these findings. 5- The future may include combining metabolic therapies like semaglutide w/ other disease modifying strategies for a more complete approach. https://sciencehub.novonordisk.com/congresses/aan2026/belmont-rausch.html #michaelokun #fixelinstitute #alzheimer